[{"id":"4887b0d3-492c-4a01-a948-a902bde00e92","acronym":"QUILT-3.013","url":"https://clinicaltrials.gov/study/NCT02751528","created_at":"2021-01-18T13:28:53.587Z","updated_at":"2024-07-02T16:36:56.322Z","phase":"Phase 1","brief_title":"QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer","source_id_and_acronym":"NCT02751528 - QUILT-3.013","lead_sponsor":"NantBioScience, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ETBX-021"],"overall_status":"Unknown status","enrollment":" Enrollment 3","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2019-08-28"}]